mefenamic acid has been researched along with furosemide in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abellán Guillén, A; Cordeiro, MN; Garrido Escudero, A; Morales Helguera, A; Pérez-Garrido, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Fujiwara, R; Koga, T; Nakajima, M; Yokoi, T | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barlow, JW; Lim, CF; Raggatt, LE; Stockigt, JR; Topliss, DJ | 1 |
| Barlow, JW; Curtis, AJ; Lim, CF; Stockigt, JR; Topliss, DJ | 1 |
| Benvenga, S; Cahnmann, HJ; Gregg, RE; Robbins, J | 1 |
| Benvenga, S; Li Calzi, L; Robbins, J | 1 |
| Hamblin, PS; Kolliniatis, E; Lim, CF; Stockigt, JR; Topliss, DJ | 1 |
| Benvenga, S; Cahnmann, HJ; Robbins, J | 1 |
| Andrikopoulou, DA; Glynou, KM; Ioannou, PC; Rusakova, NV; Tzompanaki, GM | 1 |
| Khazine, F; Simons, O | 1 |
| Katz, U; Nagel, W; Somieski, P | 1 |
| Karami-Tehrani, F; Mokarram, P; Salami, S | 1 |
| Hosseini-Baharanchi, FS; Rafieian-Kopaei, M; Raisi Dehkordi, Z | 1 |
2 review(s) available for mefenamic acid and furosemide
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for mefenamic acid and furosemide
| Article | Year |
|---|---|
A double-blind controlled crossover study to investigate the efficacy of salix extract on primary dysmenorrhea.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Dysmenorrhea; Female; Humans; Mefenamic Acid; Plant Extracts; Quality of Life; Salix; Young Adult | 2019 |
23 other study(ies) available for mefenamic acid and furosemide
| Article | Year |
|---|---|
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
Topics: beta-Cyclodextrins; Hydrophobic and Hydrophilic Interactions; Organic Chemicals; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Comet Assay; DNA Damage; Glucuronides; Glucuronosyltransferase; HEK293 Cells; Hepatocytes; Humans; Kidney | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Characterization of cytoplasmic T3 binding sites by adsorption to hydroxyapatite: effects of drug inhibitors of T3 and relationship to glutathione-S-transferases.
Topics: Amiodarone; Animals; Binding Sites; Binding, Competitive; Cytosol; Diclofenac; Dithiothreitol; Dose-Response Relationship, Drug; Durapatite; Furosemide; Glutathione Transferase; Hydrocortisone; Hydroxyapatites; In Vitro Techniques; Iopanoic Acid; Liver; Macaca fascicularis; Mefenamic Acid; Sulfobromophthalein; Taurocholic Acid; Triiodothyronine | 1992 |
Interactions between oleic acid and drug competitors influence specific binding of thyroxine in serum.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Binding, Competitive; Diflunisal; Furosemide; Humans; Kinetics; Meclofenamic Acid; Mefenamic Acid; Oleic Acid; Oleic Acids; Phenylacetates; Thyroxine; Thyroxine-Binding Proteins | 1991 |
Characterization of the binding of thyroxine to high density lipoproteins and apolipoproteins A-I.
Topics: Apolipoprotein A-I; Apolipoproteins A; Autoradiography; Binding Sites; Diclofenac; Furosemide; Lipoproteins, HDL; Lipoproteins, VLDL; Mefenamic Acid; Temperature; Thyroid Hormones; Thyroxine; Thyroxine-Binding Proteins; Time Factors | 1989 |
Effect of free fatty acids and nonlipid inhibitors of thyroid hormone binding in the immunoradiometric assay of thyroxin-binding globulin.
Topics: Binding, Competitive; Diclofenac; False Negative Reactions; Fatty Acids, Nonesterified; Furosemide; Humans; Mefenamic Acid; Phenylacetates; Radioimmunoassay; Reagent Kits, Diagnostic; Thyroxine; Thyroxine-Binding Proteins | 1987 |
Furosemide, fenclofenac, diclofenac, mefenamic acid and meclofenamic acid inhibit specific T3 binding in isolated rat hepatic nuclei.
Topics: Amiodarone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Nucleus; Diclofenac; Furosemide; In Vitro Techniques; Liver; Male; Meclofenamic Acid; Mefenamic Acid; Phenylacetates; Phenytoin; Rats; Rats, Inbred Strains; Receptors, Thyroid Hormone | 1988 |
Characterization of thyroid hormone binding to apolipoprotein-E: localization of the binding site in the exon 3-coded domain.
Topics: Affinity Labels; Amino Acid Sequence; Animals; Antibodies, Monoclonal; Apolipoproteins E; Binding Sites; Blood Proteins; Diclofenac; Exons; Furosemide; Isoelectric Focusing; Mefenamic Acid; Mice; Molecular Sequence Data; Mutation; Photochemistry; Thyroxine | 1993 |
Spectrofluorimetric determination of anthranilic acid derivatives based on terbium sensitized fluorescence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diuretics; Furosemide; Humans; Mefenamic Acid; ortho-Aminobenzoates; Spectrometry, Fluorescence; Terbium | 1998 |
[A possible adverse effect from the association of losartan-mefenamic acid in hemodialysis].
Topics: Adult; Antihypertensive Agents; Atenolol; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Furosemide; Glomerulonephritis, IGA; Humans; Hypertension; Losartan; Mefenamic Acid; Renal Dialysis | 2001 |
Selective inhibition of Cl(-) conductance in toad skin by blockers of Cl(-) channels and transporters.
Topics: Angiogenesis Inhibitors; Animals; Anion Transport Proteins; Anti-Inflammatory Agents, Non-Steroidal; Bufonidae; Bumetanide; Calcium Channel Blockers; Carrier Proteins; Chloride Channels; Chlorides; Cyclooxygenase Inhibitors; Diuretics; Dose-Response Relationship, Drug; Electric Conductivity; Eosine Yellowish-(YS); Flufenamic Acid; Fluorescent Dyes; Furosemide; Mefenamic Acid; Membrane Potentials; Niflumic Acid; Nitrobenzoates; ortho-Aminobenzoates; Patch-Clamp Techniques; Skin | 2001 |
Competition of tamoxifen with thyroxine for TBG binding: ligand binding assay and computational data.
Topics: Binding, Competitive; Diclofenac; Furosemide; Humans; Mefenamic Acid; Models, Molecular; Molecular Conformation; Tamoxifen; Thyroxine; Thyroxine-Binding Proteins | 2001 |